Armis Biopharma® News
Armis Biopharma Announces the Appointment of Michael J. Voss to CEO, replacing Ted Ziemann who is Retiring July 1st
Armis Biopharma Announces the Appointment of Michael J. Voss to CEO, replacing Ted Ziemann who is Retiring July 1stFORT COLLINS, CO (July 1, 2024) – Armis Biopharma, Inc. announced today that it has appointed Michael J. Voss as CEO, replacing Ted Ziemann who is...
Armis Biopharma® Announces Receipt of a Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds
Armis Biopharma® Announces 510(k) Clearance for VeriCyn® Wound Wash
Armis Biopharma® Announces 510(k) Clearance for VeriCyn® Wound Wash
Veriox® DECON is Shown to Kill Biological Warfare Agent, Anthrax
Armis Biopharma® Announces Release of Phase 2 Grant Awardfrom the National Institutes of Health
Armis Biopharma® Donates ArmiClenz™ Disinfectant to Convoy of Hope for Hurricane Ida victims
Armis Biopharma® Announces 510(k) Clearance for VeriFixx™ Small Bone Implant